On May 4, 2026, Masaru Matsuda, the Executive Vice President and Chief Legal Officer of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), engaged in the sale of common stock valued at a total of $192,415. The transactions were executed at weighted average prices that fell within a range of $23.2696 to $23.6106 per share.
The divestment was comprised of two separate components. The first transaction involved the sale of 7,372 shares at a weighted average price of $23.2696 per share. This specific movement was conducted under the framework of a Rule 10b5-1 trading plan. That particular plan had been adopted on June 5, 2025, and is scheduled to remain in effect until September 4, 2026. Within this transaction, the shares were sold through multiple individual trades at prices spanning from $23.1167 to $23.48.
The second component of the stock sale involved 884 shares, which were sold at a weighted average price of $23.6106 per share. Unlike the pre-planned sales, these specific shares were sold for the purpose of covering tax withholding obligations that arose from the vesting of Restricted Stock Units. These secondary transactions occurred at prices ranging between $23.16 and $23.93.
Following these recent activities, Mr. Matsuda maintains a direct ownership stake of 126,689 shares of Arcutis Biotherapeutics common stock. This filing also serves to rectify a previous reporting error; an earlier Form 4 filed on March 3, 2026, had incorrectly listed Mr. Matsuda’s beneficial ownership by an excess of 1,987 shares due to a scrivener's error.
The timing of these transactions coincides with recent financial performance metrics released by the company. Arcutis Biotherapeutics recently disclosed its first-quarter earnings for 2026, presenting a mixed financial picture. The company reported revenue of $105.4 million, which outperformed the consensus analyst expectation of $103.72 million. However, this revenue beat was offset by a loss per share that exceeded projections. While analysts had anticipated a loss of $0.05 per share, the actual reported loss stood at $0.09 per share, representing an earnings per share (EPS) surprise of -80%.
These quarterly results highlight the ongoing operational dynamics within the company as it manages costs against its revenue streams. Although the loss per share was higher than anticipated, the reported revenue exceeded forecasts and the company maintains a positive cash flow outlook. As of this report, major analyst firms have not issued any formal upgrades or downgrades in response to these latest earnings figures.
In terms of market valuation, ARQT stock has demonstrated significant movement, rising to $24.17 and marking a 69% increase over the previous year. Despite this upward trend, certain analyses suggest that the shares may still be undervalued when compared to fair value estimates, positioning the company as a notable entity for those monitoring valuation metrics.